PURPOSE: We compare the combination of orchiectomy and radiotherapy to radiotherapy alone as treatment for pelvic confined @entity263 , that is T1-4, pN0-3, M0 (TNM classification). MATERIALS AND METHODS: In this prospective study 91 @entity1 with clinically localized @entity263 were, after surgical lymph node staging, randomized to receive definitive external beam radiotherapy (46) or combined orchiectomy and radiotherapy (45). @entity1 treated with radiotherapy alone had @entity342 ablation at clinical disease progression. The effects on progression-free, disease specific and overall survival rates were calculated. RESULTS: After a median followup of 9.3 years (range 6.0 to 11.4) clinical progression was seen in 61% of the radiotherapy only @entity1 (group 1) and in 31% of the combined treatment @entity1 (group 2) (p = 0.005). The mortality was 61 and 38% (p = 0.02), and cause specific mortality was 44 and 27%, respectively (p = 0.06), in groups 1 and 2. The differences in favor of combined treatment were mainly caused by lymph node positive @entity5 . For node negative @entity5 there was no significant difference in survival rates. CONCLUSIONS: The progression-free, disease specific and overall survival rates for @entity1 with @entity263 and pelvic lymph node involvement are significantly better after combined @entity342 ablation and radiotherapy than after radiotherapy alone. These results strongly suggest that early @entity342 deprivation is better than deferred endocrine treatment for these @entity1 .

Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic XXXX with or without pelvic lymph node involvement: a prospective randomized study.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors'] @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer'] @entity342 :: ('CHEBI:50113', 'Chemical') :: ['androgen']
@entity263 :: (MESH:D011471,Disease) :: ['prostate cancer']
